Bhat Yasser M, McGrath Kevin M, Bielefeldt Klaus
Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
J Clin Gastroenterol. 2006 Feb;40(2):116-21. doi: 10.1097/01.mcg.0000196188.57543.75.
The introduction of wireless pH monitoring has been touted as a significant advance in the diagnosis of gastroesophageal reflux and associated disorders. We prospectively enrolled patients in a research registry to assess the feasibility and safety in clinical use.
All patients undergoing endoscopy with wireless pH studies (Medtronic Bravo pH system) for a 12-month period starting in April 2004 were prospectively enrolled. Probes were placed 6 cm above the endoscopically localized squamocolumnar junction. Successful completion was defined as at least 24 hours of pH recording. Safety data were obtained by review of patient diaries. All results are given as median with 25% to 75% confidence interval (CI).
A total of 217 studies with endoscopy and capsule placement were performed (65% women; median age, 51 years; range, 42-58 years) and included in the study; 1 patient refused participation in the registry and 5 studies were performed without preceding endoscopy and were excluded from this analysis. The pH study was successfully completed in 95.1%; early capsule detachment (1 hours; CI, 0-5 hours) or receiver malfunction occurred in 7 and 2 cases, respectively. There were no immediate adverse effects; 18 patients (9%) complained about significant chest discomfort, associated with odyno- or dysphagia, requiring removal of the capsule in 3 patients (1.5%). Of the completed studies, 56% were abnormal with 32.2% being abnormal on both days, whereas 16.1% and 6.9% only showed increased acid exposure on day 1 or 2, respectively. The higher likelihood of abnormal results for day 1 was associated with a significantly increased esophageal acid exposure during the first 6 hours after capsule insertion on day 1 (total time with pH < 4: 6.9%; CI, 3.2%-16.5%) compared with the corresponding time on day 2 (5.0%; CI, 0.9%-10.8%; P < 0.01), without differences esophageal acidification during the remaining time or differences in recorded activity.
Using a large registry of patients with suspected gastroesophageal reflux symptoms, our data show that wireless pH studies can be safely completed in more than 90% of patients. Whereas variability during prolonged recordings should be expected, the significantly higher likelihood of abnormal findings during the initial period of pH monitoring suggests a systematic influence of endoscopy and associated premedication, typically performed prior to capsule insertion, which needs to be considered when pH data are analyzed.
无线pH监测技术的引入被视为胃食管反流及相关疾病诊断方面的一项重大进展。我们前瞻性地将患者纳入研究登记系统,以评估其临床应用的可行性和安全性。
从2004年4月开始的12个月内,所有接受内镜检查并同时进行无线pH研究(美敦力Bravo pH系统)的患者均被前瞻性纳入研究。探头放置在内镜定位的鳞柱状上皮交界处上方6厘米处。成功完成定义为至少24小时的pH记录。通过查阅患者日记获取安全数据。所有结果均以中位数表示,并给出25%至75%的置信区间(CI)。
共进行了217例内镜检查及胶囊放置研究(65%为女性;中位年龄51岁;范围42 - 58岁)并纳入本研究;1例患者拒绝参与登记系统,5项研究未先行内镜检查,被排除在本分析之外。pH研究成功完成率为95.1%;分别有7例和2例出现早期胶囊脱落(<1小时;CI,0 - 5小时)或接收器故障。无即刻不良反应;18例患者(9%)主诉严重胸痛,伴有吞咽痛或吞咽困难,3例患者(1.5%)需取出胶囊。在完成的研究中,56%异常,其中32.2%两天均异常,而仅16.1%和6.9%分别仅在第1天或第2天显示酸暴露增加。第1天异常结果可能性较高与第1天胶囊插入后最初6小时内食管酸暴露显著增加相关(pH < 4的总时间:6.9%;CI,3.2% - 16.5%),相比之下第2天相应时间为5.0%(CI,0.9% - 10.8%;P < 0.01),其余时间食管酸化无差异,记录的活动也无差异。
通过对大量疑似胃食管反流症状患者的登记研究,我们的数据表明,超过90%的患者能够安全完成无线pH研究。尽管长时间记录期间存在变异性,但pH监测初期异常发现的可能性显著更高,提示内镜检查及相关术前用药(通常在插入胶囊前进行)存在系统性影响,在分析pH数据时需予以考虑。